132results about How to "Avoid dysfunction" patented technology

An apparatus for treating heart failure, including a conduit positioned in a hole in the atrial septum of the heart, to allow flow from the left atrium into the right atrium. The conduit is fitted with one or more emboli barriers or one-way valve members, to prevent thrombi or emboli from crossing into the left side circulation.

The present invention comprises a method of protecting organs or tissue susceptible to reperfusion-induced dysfunction after ischemia. The method comprises parenterally administering to a patient a therapeutical composition containing natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or a mixture thereof. Alternatively, organ or tissue transplants can be contacted with natural alpha-1 acid glycoprotein, natural alpha-antitrypsin or mixtures by perfusing or flushing them with a solution containing natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or mixtures thereof in a concentration of 0.1 to 5 g / l.

An ultrasonic probe is provided with a CMUT chip having a plurality of transducer elements that change electromechanical coupling coefficients or sensitivities in accordance with a bias voltage to transmit and receive ultrasonic waves, an electric conducting layer formed on the ultrasonic irradiation side of the CMUT chip, an acoustic lens arranged on the ultrasonic irradiation side of the CMUT chip, an insulating layer formed in the direction opposite to the ultrasonic irradiation side of the acoustic lens, a housing unit that stores the CMUT chip in which the electric conducting layer and the insulating layer are fixed with an adhesive and the acoustic lens, wherein the insulating layer is formed by the material that includes at least either silicon oxide or paraxylene to prevent a solvent of the adhesive from soaking into the adhered portion.

A gait management apparatus applies stimulation to a user suffering from a neurological disease (such as Parkinson's Disease) gait dysfunction. Motion sensors are arranged to be worn by a patient, and electrical stimulation electrodes are on the legs for stimulation. A controller receives motion sensing signals, and processes these signals to generate stimulation signals for operation of the electrodes to stimulate limb movement upon detection of a gait abnormality. There may be a user actuator for user actuation of electrical stimulation, and the inputs may be a series of taps. The controller may provide signals to prevent occurrence of freezing of gait when it senses that a patient is walking or has an intention to walk. Also, it may apply stimulation at an intensity level which is insufficient for functional muscle stimulation but sufficiently high to trigger activation of efferent nerves.

The present invention comprises a method of protecting organs or tissue susceptible to reperfusion-induced dysfunction after ischemia. The method comprises parenterally administering to a patient a therapeutical composition containing natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or a mixture thereof. Alternatively, organ or tissue transplants can be contacted with natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or mixtures by perfusing or flushing them with a solution containing natural alpha-1 acid glycoprotein, natural alpha-1 antitrypsin or mixtures thereof in a concentration of 0.1 to 5 g / l.

An embodiment of the invention provides a proximity sensor calibration method and device, a mobile terminal and a computer readable medium and belongs to the technical field of mobile communication. The method includes: when the starting of the proximity sensor is detected, acquiring the proximity value collected by the proximity sensor according to preset calibration parameters; judging whether the proximity value is larger than a preset standard value and smaller than a preset maximum threshold; if so, updating the preset calibration parameters according to the difference between the proximity value and the preset standard value. The method has the advantages that the preset calibration parameters are updated according to the difference between the proximity value and the preset standardvalue, so that the proximity value collected by the proximity sensor according to the updated preset calibration parameters is closer to the preset standard value, and the measuring accuracy rate ofthe proximity tactile sensor is increased.

A catheter for blood removal that is to be provided in the coronary sinus via the inferior vena cava to remove the blood in the coronary sinus from the body wherein: the catheter for blood removal has a straight back end shaft, a curved front end shaft connected in the front end side of the back end shaft, a hub connected in the back end side of the back end shaft and a blood removal lumen extending from the back end of the catheter for blood removal to the front end thereof; the front end shaft comprises a first straight part, a first curve part following the first straight part, a second curve part following the first curve part, a second straight part following the second curve part, a third curve part following the second straight part and a third curve part following the third straight part.

Acid compositions for ruminants containing a plurality of acid-neutralizing salts with pKa's effective at different ruminant gastrointestinal pH ranges and an active probiotic culture capable of stimulating the growth and concentration of beneficial acid-consuming rumen microorganisms. Methods for preventing clinical and sub-clinical acidosis in ruminants with the acid-neutralizing salts and feed compositions to which the acid-neutralizing salts have been added are also disclosed.

Shilajit in a standardized composition produces a significant improvement in several cardiovascular parameters including RI, AIx and SEVR. Further, significant reductions in malondialdehyde and increases in nitric oxide levels are provided suggesting improvement in endothelial function. Shilajit may be used to reduce inflammatory biomarker HsCRP levels significantly compared to baseline and placebo. Additionally, Shilajit can provide significant improvement in lipid parameters including total cholesterol, LDL-C, and HbA1c (%) Inhibition of platelet aggregation using Shilajit performed using ADP as aggregant also provides highly significant inhibition of platelet aggregation compared to baseline and with placebo. Thus, Shilajit may be used for improvement of endothelial function and to help reduce cardiovascular morbidity, particularly for the diabetic individual.

The present invention includes methods for treating Meibomian gland dysfunctions. The invention also includes methods for improving tear lipid composition, for treating abnormal Meibomian gland secretion and for normalizing Meibomian gland secretions.

A method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers is disclosed. The method firstly provides a pharmaceutical composition having a biologically compatible peptide hydrogel formed by a plurality of self-assembling peptide nanofibers and selectively having at least one type of autologous stem cells mixed with the self-assembling peptide nanofibers, and then the pharmaceutical composition is administered to an entire infarcted area of myocardium tissue with myocardial infarction by intramyocardial or transendocardial injection. Thus, adverse cardiac remodeling and dysfunction after acute infraction can be attenuated, while the therapeutic myocardial angiogenesis, the myocardial capillary density and potential myogenesis can be enhanced.

This invention is directed toward herbal compositions and methods of treatment for prevention or treatment of erectile dysfunction disorders and ameliorating symptoms thereof and as a preventative measure against erectile dysfunction. The methods comprise administering a therapeutically effective composition of matter comprising the following herbal and other components: Herba cynomorii, Rhizhomnas atractylodis macrocephalae, Radix rehmannia glutinosea longui, Herba epimedii, Fructus lycii, Fructus schisandrae chinensis, Radix poloygoni multiflor, Cortex cinnamonia cassiae, Fructus amoni, and Radix ginseng. The components of the invention interact synergistically once consumed to remedy or prevent erectile dysfunction when taken as prescribed. The invention is completely herbal in composition and does not contain any hormones, morphine, or any of the compositions of matter know by trade names Viagra, Cialis, Sildenafil or Vardenafil. Side benefits of taking this dietary supplement include increased energy, improved immune system strength, and improved erectile activity in men without erectile dysfunction.

The invention discloses a method for preparing a propolis, bee pollen and royal jelly nutritive mixture, which is characterized by comprising the following steps: adding high-purity propolis into 75 percent alcohol for heating and melting to prepare propolis liquid; mixing and stirring the propolis liquid and broken wall bee pollen uniformly, putting the mixture into a 50 DEG C low blowing dry box for full drying, taking the mixture out, mixing the mixture with freeze-dried powder of royal jelly, grinding the mixture into fine powder with 200 meshes by a fluid jet mill and packaging the fine powder. The method has the advantages of solving the difficult problems of difficult decomposition of the propolis, sterilization of the bee pollen and no high-temperature resistance of the royal jelly, simultaneously obtaining the nutrition and health care functions of three bee products, improving the absorptivity of the propolis, preventing nutrition of the three natural bee products from being damaged, having good synergism on the medical care function of the mixture of the three, and even improving the efficacy by 3 to 5 times. The preparation method is scientific, simple and convenient, and has low cost, and safety and reliability; and the mixture is convenient to take.

The invention includes a compound of formula I:wherein R1, Y, A, n, R4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and / or treating cognitive disorders or impairment, traumatic and / or ischemic injuries of the central and peripheral nervous system and / or psychiatric disorders in animals, especially humans.

The invention discloses a charging metering method for a charging station. A charging metering system of the charging station comprises a main processor, a power supply module, a display module, a communication module, an electric energy metering module, a data read-write module, a data storage module, an output module, an output port, a door lock and charging control module and a charging door, wherein the power supply module, the display module, the communication module, the electric energy metering module, the data read-write module, the data storage module, the output module, the output port and the door lock and charging control module are electrically connected with the main processor, and the charging door is controlled to be opened or closed by the door lock and charging control module. The charging metering method has the advantages that the modular design is adopted, and the coupling degree among all functions is reduced; the man-machine interaction practicability and the humanized use experience of the charging metering system are enhanced through the output port, and the reserved expansion space is provided for the system, and the function expansion of the hardwire can be carried out; the high-integration degree and the intelligentization of the system are realized through the automatic updating and the maintenance function of the system; and each function is realized in different stages, the stages are divided according to the function requirement, the phased implementation is carried out according to the importance program, and the function repetition or the function turbulence caused by the mutual influence because of the simultaneous communication among the modules is avoided.

The invention discloses a flexible display, a manufacturing method thereof and a piece of electronic equipment. The flexible display comprises a flexible display screen, a driving chip and a supporting device, wherein the flexible display screen comprises a flexible substrate that comprises a display area and a binding area; the driving chip is bound to the binding area; the supporting device covers the flexible substrate, and the supporting device located at the position of the binding area is provided with an opening. As the supporting device covers the entire flexible substrate, the flexible display and the manufacturing method thereof and the electronic equipment disclosed by the invention increase the strength of the bonding region, prevent the problem of poor function of the flexiblescreen body caused by that the signal lines are broken during peeling, reduce the attachment process of the support film, and make the flexible display thinner at the same time.

The invention discloses a lactic acid bacteria complex microbial agent for treating depression. The lactic acid bacteria complex microbial agent is a JF complex lactic acid bacteria preparation, and mainly comprises lactobacillus helveticus and lactobacillus fermentum, wherein the lactobacillus helveticus and lactobacillus fermentum are combined according the weight ratio of 1:3. The lactic acid bacteria complex microbial agent provided by the invention has the advantages that an anti-depression effect is realized by restoring healthy flora and regulating bacteria, intestinal and brain axis functions, and the lactic acid bacteria complex microbial agent has a good therapeutic effect for depression, and the effective rate is 90% or higher, not only is peripheral inflammation reduced, but also neuroinflammation is improved, the neurogenesis in brain is increased, and the brain neuroplasticity is enhanced.

The use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the manufacture of a medicament for the prevention and / or treatment of benign prostatic hyperplasia (BPH) and associated symptoms.

The present invention relates to methods of treating Alzheimer's Disease which utilize agents that increase neuronal phosphotidylinositol 4,5-biphosphate (PIP2), and to differentiated stem cell-based assay systems that may be used to identify agents that modulate phosphoinositide levels and thereby treat a variety of diseases. It is based, at least in part, on the discovery that edelfosine, an agent that increases PIP2 levels by inhibiting an enzyme that catalyzes PIP2 breakdown, decreases levels of neurotoxic A&bgr;42 peptide, particularly in cells expressing a mutant presenilin gene associated with Familial Alzheimer's Disease.

A Chinese medicine for treating the trauma of animal is prepared from primary medicine, secondary medicine and matrix in the ratio of (15-20%): (3-4.4%) and (75.6-82%).

The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway, and for treating Hedgehog related disorders such as cancers (e.g., medulloblastoma). In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptch loss-of-function, Hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function by administering to a mammal combinations of Smoothened inhibitors (e.g., a compound of Formula I, Formula II, or Formula III, or any of the compounds listed herein or incorporated by reference) and cholesterol biosynthesis pathway inhibitors (e.g., statins), Gli inhibitors, and / or Phosphatidylinositol 3-kinase (PI3K) inhibitors.

A method for protection of a mammal that has impaired glucose tolerance or early stage diabetes mellitus from developing overt or insulin dependent diabetes comprises administering an orally effective dose of a pharmaceutical formulation comprising insulin at nighttime, e.g., at or shortly before bedtime.

The invention discloses a charge metering system and metering method for a charging station. The system comprises a main processor, a power module, a display module, a communication module, an electric energy metering module, a data read-write module, a data memory module, an output module, an output port, a gate lock and charge control module and a charging gate, wherein the power module, the display module, the communication module, the electric energy metering module, the data read-write module, the data memory module, the output module, the output port and the gate lock and charge controlmodule are electrically connected with the main processor, and on and off of the charging gate are controlled by the gate lock and charge control module. Degree of coupling between functions is reduced by means of the modular design, man-computer interaction practicality and humanized using experiences of the charge metering system are enhanced by means of the output port, and functional expanding of hardware can be realized as an expanding space is reserved for the system. High integration level and intelligent level of the system are achieved due to the automatic updating and maintenance functions of the system. Functions are realized at different stages according to importance procedures, the stages are divided according to function requirements, and thereby functional repetition or functional chaos caused by mutual influences of modules in simultaneous interaction communication can be avoided.

The embodiment of the invention provides a vehicle data transmission method and a system. The method comprises the following steps: obtaining a target data set aimed at a target functional system; Analyzing each target network data, obtaining the target sampling time point of each target network data; judging whether each target sampling time point is the current sampling time point; If yes, all the target network data in the target data set are packaged and the packaged target information is sent to the target control node, so that the target control node performs corresponding function control according to the target information; if not, caching the target sampling time point as the target network data of the current sampling time point, and updating the target network data which is notthe current sampling point, and judging whether each target sampling time point is the current sampling time point. When the method provided by the embodiment of the invention is used for data transmission, the problem that the functional effect is reduced due to network data asynchronization is avoided.

The present invention relates to a nucleic acid molecule encoding a K94A / K447A mutant of wild type p90 ribosomal S6 kinase (p90RSK) and DNA constructs, expression vectors, and hosts including the mutant p90RSK-encoding molecule. The present invention also relates to two transgenic non-human animal models of ischemic reperfusion (I / R) damage, the first animal having a transgene encoding a mutant p90RSK that is rendered kinase inactive for S703 phosphorylation of NHE1 and the second animal having a transgene encoding for cardiac-specific overexpression of wild type p90RSK in the animal that provides a model for diabetic cardiomyopathy. Also provided are methods for generating transgenic non-human animal models of ischemic reperfusion (I / R) damage; for using the transgenic cells for identifying an agent capable of inhibiting p90RSK-induced I / R damage; for identifying agents that modulate I / R injury resulting from an ischemic event; and for treating individuals to inhibit I / R injury following an ischemic event.

The present invention relates to methods of treatment and / or prevention of pulmonary hypertension and to methods of treatment and / or prevention of cardiac remodelling and more specifically to cardiac remodelling induced by systemic hypertension in a mammal, particularly a human being. In particular, the invention shows a novel, negative role for urokinase-type plasminogen activator in the pathogenesis of cardiac remodelling, leading to subsequent cardiac dysfunction, and in the pathogenesis of pulmonary hypertension usually complicated by subsequent right ventricular hypertrophy. Consequently, the use of selective inhibitors of u-PA activity can be of benefit for treatment of patients suffering from pulmonary hypertension and / or cardiac remodelling.

The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy. Based on these findings, pharmaceutical compositions are provided for the prevention and / or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom, which comprise an HMGB1 fragment peptide having a particular amino acid sequence.